Medicine
Zepatier 50 mg/100 mg tablet
Zepatier 50 mg/100 mg tablet is a prescription medicine containing Elbasvir and Grazoprevir for oral use, marketed by Merck Sharp & Dohme, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store ZEPATIER at 20°C to 25°C (68°F to 77°F), excursions permitted between…
Key facts
- Active ingredient (INN)
- Elbasvir and Grazoprevir
- Brand
- Zepatier
- Strength
- 50 mg/100 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 2 dose packs
- Marketing authorisation holder
- Merck Sharp & Dohme
- Manufacturer
- Merck Sharp & Dohme
- Origin register
- US FDA, United States
- Storage
- Store ZEPATIER at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (between 59°F to 86°F). Store ZEPATIER in the original blister package until use to protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AP54 Elbasvir and Grazoprevir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 January 2016
- Identifiers
- RxCUI 1734636, 1734642DailyMed set ID 164dc02a-9180-426a-b8b5-04ab39d2bbd4NDC 0006-3074Application NDA208261
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 dose pack in 1 carton / 14 tablet, film coated in 1 dose pack | 0006-3074-02 | Merck Sharp & Dohme | 28 January 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Elbasvir and Grazoprevir is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor and a hepatitis C virus NS5A inhibitor. It is available as tablets for oral use. MedsAcross supplies Elbasvir and Grazoprevir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Elbasvir and GrazoprevirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZEPATIER prescribing information (Merck Sharp & Dohme) · U.S. National Library of Medicine, DailyMed
- Zepatier: European public assessment report (EPAR) · European Medicines Agency
Need Zepatier 50 mg/100 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.